A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma

被引：7
|
作者：
Suarez-Kelly, Lorena P. [1 ,2 ]
Levine, Kala M. [1 ,2 ]
Olencki, Thomas E. [2 ,3 ]
del Campo, Sara E. Martin [4 ]
Streacker, Elizabeth A. [5 ]
Brooks, Taylor R. [6 ,7 ]
Karpa, Volodymyr I. [1 ,2 ]
Markowitz, Joseph [1 ,2 ,8 ]
Bingman, Anissa K. [2 ,9 ,10 ]
Geyer, Susan M. [2 ,9 ,10 ]
Kendra, Kari L. [2 ,3 ]
Carson, William E. [1 ,2 ,4 ]
机构：
[1] Ohio State Univ, Arthur G James Canc Hosp, Comprehens Canc Ctr, N924 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA
[2] Richard J Solove Res Inst, N924 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Arthur G James Canc Hosp, Med Oncol, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA
[5] Promed Toledo Hosp, Toledo, OH USA
[6] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA
[7] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[9] Ohio State Univ, Coll Med, Dept Biomed Informat, Columbus, OH 43210 USA
[10] Ohio State Univ, Dept Internal Med, Arthur G James Canc Hosp, Hematol, Columbus, OH 43210 USA
来源：
CANCER IMMUNOLOGY IMMUNOTHERAPY | 2019年 / 68卷 / 04期
基金：
美国国家卫生研究院;
关键词：
RANDOMIZED PHASE-III; CUTANEOUS MELANOMA; IFN-ALPHA; TRIAL; TOXICITIES; IPILIMUMAB; INHIBITORS; NIVOLUMAB; SURGERY; MM;
D O I：
10.1007/s00262-019-02308-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：619 / 629
页数：11
相关论文
共 50 条
  • [1] A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
    Lorena P. Suarez-Kelly
    Kala M. Levine
    Thomas E. Olencki
    Sara E. Martin del Campo
    Elizabeth A. Streacker
    Taylor R. Brooks
    Volodymyr I. Karpa
    Joseph Markowitz
    Anissa K. Bingman
    Susan M. Geyer
    Kari L. Kendra
    William E. Carson
    [J]. Cancer Immunology, Immunotherapy, 2019, 68 : 619 - 629
  • [2] LONG-TERM ADJUVANT THERAPY OF HIGH-RISK MALIGNANT-MELANOMA WITH INTERFERON-ALPHA-2B
    KOKOSCHKA, EM
    TRAUTINGER, F
    KNOBLER, RM
    POHLMARKL, H
    MICKSCHE, M
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (06) : S193 - S197
  • [3] Adjuvant therapy of high-risk melanoma: The role of high-dose interferon alpha-2b
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, T
    Borden, E
    Blum, R
    [J]. ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 251 - 257
  • [4] A pilot study of interferon-alpha-2b dose reduction in melanoma: High dose interferon is not necessary for optimal activation of immune signal transduction.
    Levine, Kala M.
    Del Campo, Sara E. Martin
    Brooks, Taylor
    Streaker, Elizabeth
    Sprague, Leslee
    Karpa, Volodymr
    Markowitz, Joseph
    Bingman, Anissa
    Geyer, Susan Michelle
    Olencki, Thomas
    Kendra, Kari Lynn
    Carson, William Edgar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Adjuvant high-dose interferon therapy for high-risk melanoma
    Ready, N
    Weinstock, MA
    [J]. ARCHIVES OF DERMATOLOGY, 2003, 139 (12) : 1635 - 1637
  • [6] Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma
    Yamazaki, Naoya
    Uhara, Hisashi
    Wada, Hidefumi
    Matsuda, Kenji
    Yamamoto, Keiko
    Shimamoto, Takashi
    Kiyohara, Yoshio
    [J]. JOURNAL OF DERMATOLOGY, 2016, 43 (10): : 1146 - 1153
  • [7] Update on adjuvant interferon therapy for high-risk melanoma
    Agarwala, SS
    Kirkwood, JM
    [J]. ONCOLOGY-NEW YORK, 2002, 16 (09): : 1177 - 1187
  • [8] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
    Jonasch, E
    Kumar, UN
    Linette, GP
    Hodi, FS
    Soiffer, RJ
    Ryan, BF
    Sober, AJ
    Mihm, MC
    Tsao, H
    Langley, RG
    Cosimi, BA
    Gadd, MA
    Tanabe, KK
    Souba, W
    Haynes, HA
    Barnhill, R
    Osteen, R
    Haluska, FG
    [J]. CANCER JOURNAL, 2000, 6 (03): : 139 - 145
  • [9] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [10] Feasibility of high-dose interferon-α2b adjuvant therapy for high-risk resected cutaneous melanoma
    Muggiano, A
    Mulas, C
    Fiori, B
    Liciardi, G
    Pintus, M
    Tanca, L
    Tedde, A
    Turno, R
    Desogus, A
    [J]. MELANOMA RESEARCH, 2004, 14 (02) : S1 - S7
12345